Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial

Katzenstein, Howard M.; Langham, Max R.; Malogolowkin, Marcio H.; Krailo, Mark; Towbin, Alexander J.; McCarville, M. Beth; Finegold, Milton J.; Ranganathan, Sarangarajan; Dunn, Stephen P.; McGahren, Eugene D.; Tiao, Gregory M.; O’Neill, Allison F.; Qayed, Muna; Furman, Wayne L.; Xia, Chengcai; Rodríguez‐Galindo, Carlos; Meyers, Rebecka L.

doi:10.1016/s1470-2045(18)30895-7

Cited by 78 publications

(72 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Notably, the relapsed tumor from this patient had increased mutational burden accompanied by acquisition of COSMIC signature 35, which is known to be associated with exposure to cisplatin ( Supplementary Fig. S7B), a chemotherapy drug used as part of the standard of care for hepatoblastoma (52). proposed to be induced by ALL treatment were also detected exclusively in relapsed B-ALL samples ( Supplementary Fig.…”

Section: Use Case 1: Classify Pediatric Cancers By Rna-seq Expressionmentioning

confidence: 90%

St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem

et al. 2021

View full text Add to dashboard Cite

Effective data sharing is key to accelerating research to improve diagnostic precision, treatment efficacy, and long-term survival in pediatric cancer and other childhood catastrophic diseases. We present St. Jude Cloud (https://www.stjude.cloud), a cloud-based data-sharing ecosystem for accessing, analyzing, and visualizing genomic data from >10,000 pediatric patients with cancer and long-term survivors, and >800 pediatric sickle cell patients. Harmonized genomic data totaling 1.25 petabytes are freely available, including 12,104 whole genomes, 7,697 whole exomes, and 2,202 transcriptomes. The resource is expanding rapidly, with regular data uploads from St. Jude's prospective clinical genomics programs. Three interconnected apps within the ecosystem—Genomics Platform, Pediatric Cancer Knowledgebase, and Visualization Community—enable simultaneously performing advanced data analysis in the cloud and enhancing the Pediatric Cancer knowledgebase. We demonstrate the value of the ecosystem through use cases that classify 135 pediatric cancer subtypes by gene expression profiling and map mutational signatures across 35 pediatric cancer subtypes. Significance: To advance research and treatment of pediatric cancer, we developed St. Jude Cloud, a data-sharing ecosystem for accessing >1.2 petabytes of raw genomic data from >10,000 pediatric patients and survivors, innovative analysis workflows, integrative multiomics visualizations, and a knowledgebase of published data contributed by the global pediatric cancer community. This article is highlighted in the In This Issue feature, p. 995

show abstract

Section: Use Case 1: Classify Pediatric Cancers By Rna-seq Expressionmentioning

confidence: 90%

St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem

et al. 2021

View full text Add to dashboard Cite

show abstract

“…For HB which is unresectable at diagnosis, both SIOPEL and Children's Oncology Group (COG) recommend neoadjuvant chemotherapy with subsequent consideration of LT to ensure complete tumor removal. Until very recently, the chemotherapy approach utilized by each cooperative group differed both in chemotherapy agents utilized and scheduling [53][54][55][56]. The COG uses doxorubicin and 5-fluorouracil, and vincristine (C5VD) where the SIOPEL group has focused more on shorter frequency use of platinum agents with or without doxorubicin [53][54][55][56][57][58].…”

Section: Chemotherapymentioning

confidence: 99%

Liver Transplantation for Pediatric Liver Cancer

Sindhi

Rohan

Tadros

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

Unresectable hepatocellular carcinoma (HCC) was first removed successfully with total hepatectomy and liver transplantation (LT) in a child over five decades ago. Since then, children with unresectable liver cancer have benefitted greatly from LT and a confluence of several equally important endeavors. Regional and trans-continental collaborations have accelerated the development and standardization of chemotherapy regimens, which provide disease control to enable LT, and also serve as a test of unresectability. In the process, tumor histology, imaging protocols, and tumor staging have also matured to better assess response and LT candidacy. Significant trends include a steady increase in the incidence of and use of LT for hepatoblastoma, and a significant improvement in survival after LT for HCC with each decade. Although LT is curative for most unresectable primary liver sarcomas, such as embryonal sarcoma, the malignant rhabdoid tumor appears relapse-prone despite chemotherapy and LT. Pediatric liver tumors remain rare, and diagnostic uncertainty in some settings can potentially delay treatment or lead to the selection of less effective chemotherapy. We review the current knowledge relevant to diagnosis, LT candidacy, and post-transplant outcomes for these tumors, emphasizing recent observations made from large registries or larger series.

show abstract

“…Notably, the relapsed tumor from this patient had increased mutational burden accompanied by acquisition of COSMIC signature 35, which is known to be associated with exposure to cisplatin ( Supp. Figure 4B ), a chemotherapy drug used as part of the standard of care for hepatoblastoma (58). Signature 35 and signature 31, also associated with cisplatin, were found in osteoblastomas and ependymomas as previously reported (59), as well as in retinoblastoma and Ewing’s sarcoma, all of which employ cisplatin for treatment.…”

Section: Resultsmentioning

confidence: 99%

St. Jude Cloud—a Pediatric Cancer Genomic Data Sharing Ecosystem

McLeod

Gout

Zhou

et al. 2020

Preprint

View full text Add to dashboard Cite

Effective data sharing is key to accelerating research that will improve the precision of diagnoses, efficacy of treatments and long term survival of pediatric cancer and other childhood catastrophic diseases. We present St. Jude Cloud (https://www.stjude.cloud), a cloud based data sharing ecosystem developed via collaboration between St. Jude Children's Research Hospital, DNAnexus, and Microsoft, for accessing, analyzing and visualizing genomic data from >10,000 pediatric cancer patients, long term survivors of pediatric cancer and >800 pediatric sickle cell patients. Harmonized genomic data totaling 1.25 petabyes on St. Jude Cloud include 12,104 whole genomes, 7,697 whole exomes and 2,202 transcriptomes, which are freely available to researchers worldwide. The resource is expanding rapidly with regular data uploads from St. Jude's prospective clinical genomics programs, providing public access as soon as possible rather than holding data back until publication. Three interconnected apps within the St. Jude Cloud ecosystem Genomics Platform, Pediatric Cancer Knowledgebase (PeCan) and Visualization Community provide a unique experience for simultaneously performing advanced data analysis in the cloud and enhancing the pediatric cancer knowledgebase. We demonstrate the value of the St. Jude Cloud ecosystem through use cases that classify 48 pediatric cancer subtypes by gene expression profiling and map mutational signatures across 35 subtypes of pediatric cancer.

show abstract

Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial

Cited by 78 publications

References 18 publications

St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem

St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem

Liver Transplantation for Pediatric Liver Cancer

St. Jude Cloud—a Pediatric Cancer Genomic Data Sharing Ecosystem

Contact Info

Product

Resources

About